Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Interest Expenses (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Interest Expenses for 15 consecutive years, with $548000.0 as the latest value for Q1 2025.

  • Quarterly Interest Expenses rose 1511.76% to $548000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $548000.0 through Dec 2025, up 206.15% year-over-year, with the annual reading at $548000.0 for FY2025, 206.15% up from the prior year.
  • Interest Expenses for Q1 2025 was $548000.0 at Plus Therapeutics, up from $57000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $548000.0 in Q1 2025, with the low at $27000.0 in Q2 2024.
  • Average Interest Expenses over 5 years is $156687.5, with a median of $111500.0 recorded in 2022.
  • The sharpest move saw Interest Expenses crashed 75.89% in 2024, then skyrocketed 1511.76% in 2025.
  • Over 5 years, Interest Expenses stood at $232000.0 in 2021, then tumbled by 52.16% to $111000.0 in 2022, then plummeted by 44.14% to $62000.0 in 2023, then fell by 8.06% to $57000.0 in 2024, then skyrocketed by 861.4% to $548000.0 in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $548000.0, $57000.0, and $61000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.